Related Experiment Video
Updated: May 16, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
HCV's days are numbered: next-generation direct-acting antivirals and host-targeting agents
Beatriz Calle Serrano1, Michael P Manns
1Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Abstract:
Chronic hepatitis C affects approximately 170 million people worldwide and is one of the leading causes of liver-related morbidity and mortality. Until 2011, the only therapeutic option was combination therapy of pegylated interferon and ribavirin, with efficacy rates around 50% and plenty of side effects. In the past months, important steps have been made towards a more effective antiviral therapy. However, we are still far from both highly efficient and well-tolerable ideal therapy. The development of new drugs against HCV is a very dynamic field. This review summarizes the up-to-date knowledge of the most significant anti-HCV compounds in development.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Subviral Agents
Retroviruses
Size and Structure of Viral Genomes
Viruses with RNA Genomes

